
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.03 | 1.03 | 0.00 |
Shares | 98.97 | 98.97 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 24.39 | 24.14 |
Price to Book | 7.32 | 4.65 |
Price to Sales | 5.04 | 3.60 |
Price to Cash Flow | 18.08 | 15.81 |
Dividend Yield | 1.64 | 1.28 |
5 Years Earnings Growth | 9.65 | 10.69 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 27.31 | 13.70 |
Consumer Defensive | 21.91 | 6.00 |
Technology | 21.34 | 28.59 |
Communication Services | 12.16 | 9.23 |
Consumer Cyclical | 8.90 | 12.18 |
Financial Services | 5.11 | 14.94 |
Industrials | 3.27 | 12.53 |
Number of long holdings: 29
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Meta Platforms | US30303M1027 | 8.16 | 769.30 | +0.98% | |
Microsoft | US5949181045 | 7.36 | 522.04 | +0.23% | |
Stryker | US8636671013 | 6.58 | 377.58 | +0.32% | |
Philip Morris | US7181721090 | 6.22 | 170.18 | +1.20% | |
Novo Nordisk B | DK0062498333 | 5.44 | 323.1 | +4.60% | |
Visa A | US92826C8394 | 5.02 | 336.78 | +1.41% | |
L'Oreal | FR0000120321 | 4.86 | 384.35 | +0.58% | |
ADP | US0530151036 | 4.85 | 305.81 | +0.76% | |
Waters | US9418481035 | 4.63 | 281.20 | +1.15% | |
IDEXX Labs | US45168D1046 | 3.97 | 658.06 | +1.23% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fundsmith Equity I Acc | 11.55B | -1.89 | 8.05 | 13.27 | ||
Fundsmith Equity R Acc | 527.29M | -2.19 | 7.40 | 12.58 | ||
Fundsmith Equity R Inc | 5.09M | -2.19 | 7.40 | 12.58 | ||
Fundsmith Equity T Acc | 3.51B | -1.94 | 7.94 | 13.15 | ||
Fundsmith Equity T Inc | 208.72M | -2.06 | 7.94 | 13.15 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review